Insulin Clinics / Special situations

Cost and access

Insulin should not be a financial decision, but in the United States it often is. This page covers what your real options are, including the ones most people are not told about.

Last updated: October 2026 · Based on CMS Medicare rules and published manufacturer, Civica, and CalRx program terms (see sources below) · General information, not medical advice — see our editorial policy

Why insulin is expensive in the U.S.

Insulin was invented in 1921 and the original patent was sold for one dollar so that, in the inventors' words, "insulin belongs to the world." A century later, U.S. list prices for analog insulins reached roughly $250–$300 or more per vial, far above prices for the same products in Canada or the U.K. All three major manufacturers announced large list-price cuts on several insulins in 2023–2024, but what you actually pay still depends heavily on your coverage.

Several factors drive U.S. prices:

• Three manufacturers — Eli Lilly, Novo Nordisk, and Sanofi — make most of the insulin sold here.
• List prices and net prices diverge. The list price is what shows on a pharmacy bill; the net price (after rebates to pharmacy benefit managers and insurers) is much lower. Patients with deductibles or no insurance pay something close to the list price; insurers and large purchasers do not.
• Patent strategies have kept biosimilar competition limited compared with other drug classes, though this is changing.
• The PBM (pharmacy benefit manager) system ties drug coverage to rebates, which historically rewarded high list prices.

This is not your fault, and it is not your prescriber's fault. It is the system you are navigating. The following sections are about the levers that actually exist.

The $35 copay cap (Medicare)

The federal Inflation Reduction Act caps out-of-pocket cost for covered insulin at $35 for a month's supply of each covered insulin product for people on Medicare Part D (since January 2023) and for insulin used in a pump covered under Part B (since July 2023; $105 for a three-month supply). This was the law as of October 2026. No deductible applies to the capped insulin. If you are on Medicare and paying more than $35 for a month's supply of a covered insulin, call your plan and ask them to check — it may be a processing error, or the product may not be on your plan's formulary.

Many states have passed their own caps for state-regulated commercial insurance, commonly in the range of about $25 to $100 per month. These are state-by-state and do not apply to self-funded employer plans (which are federally regulated). Your state insurance commissioner's website will list current rules.

Medicaid covers insulin in every state, usually with a small copay or none. If you have lost a job or income, or lost other coverage, check whether you or your children now qualify for Medicaid or CHIP.

Manufacturer copay caps and patient assistance

Each of the three major insulin manufacturers runs a program that limits out-of-pocket cost to about $35 a month for many patients. Eligibility rules differ: Lilly's and Novo Nordisk's $35 programs generally exclude people with Medicare, Medicaid, or other government insurance, while Sanofi's program, since January 2026, is open to anyone with a prescription for a Sanofi insulin, including people on Medicare. Programs change, so confirm details on the manufacturer's website before counting on a number. Program phone numbers are listed on those websites.

The patient assistance programs (PAPs) — separate from the cash savings cards — can provide free insulin for people whose household income falls below each program's threshold and who meet its insurance rules. They usually take a few weeks to set up, and insulin may be shipped to you or to your prescriber depending on the program.

Biosimilars, follow-on brands, and unbranded insulins

Several lower-cost alternatives exist. Some are biosimilars; others are follow-on brands made by another company (Basaglar, Admelog) or unbranded versions of a brand sold by the same manufacturer:

• Insulin glargine: Basaglar (Lilly — follow-on brand); unbranded insulin glargine-yfgn (Biocon — interchangeable biosimilar; the branded Semglee version has been reported discontinued at the end of 2025, so check current availability); Civica/CalRx insulin glargine-yfgn (interchangeable; see below); and Rezvoglar (Lilly — interchangeable biosimilar).
• Insulin lispro: Lilly's unbranded Insulin Lispro (the same product as Humalog) at a lower list price; Admelog (Sanofi — follow-on brand).
• Insulin aspart: Novo Nordisk discontinued its unbranded Insulin Aspart at the end of 2025, saying brand NovoLog's reduced list price made it redundant. Biosimilars to NovoLog include Merilog (Sanofi) and Kirsty (Biocon — interchangeable, FDA-approved in 2025); check with your pharmacy which are stocked.

"Interchangeable" biosimilars (for example insulin glargine-yfgn, Rezvoglar, and Kirsty) can be substituted for the brand-name product by a pharmacist without contacting the prescriber, where state law allows. For other alternatives, the pharmacist needs the prescriber's authorization or a new prescription. If you are paying full price for brand-name insulin, ask the pharmacist whether a lower-cost version exists for what you take and what it would cost.

The Walmart ReliOn line

Walmart sells some insulins under its ReliOn brand. Human insulins in this line have been priced at roughly $25 per vial in recent years (check current prices in store):

• ReliOn Novolin R — regular human insulin (short-acting).
• ReliOn Novolin N — NPH (intermediate-acting).
• ReliOn 70/30 — premixed NPH/regular.
• ReliOn NovoLog — insulin aspart (rapid-acting analog), introduced in 2021 at about $73 per vial. That was well below analog list prices then; since Novo Nordisk's 2024 list-price cuts, brand NovoLog's list price is similar.

Important caveats:

• Regular and NPH are not interchangeable with analog insulins. Regular insulin needs to be taken about 30 minutes before meals, not at the start of a meal. NPH peaks about 4–12 hours after injection, which is different from glargine, detemir, or degludec. Switching from analog to human insulin without a clinician's plan can cause serious problems.
• Some are sold without a prescription in most U.S. states (human regular, NPH, and 70/30); analog insulins, including ReliOn NovoLog, require a prescription.
• For people with type 1 diabetes, switching from analog to regular and NPH is sometimes done in genuine financial emergencies but should always involve the care team — the timing differences make hypoglycemia and DKA risk meaningfully higher.
• For type 2 diabetes on basal alone, NPH at bedtime is a reasonable lower-cost option for many people, but should still be a medical decision rather than a self-substitution.

If you have been quietly switching to ReliOn because you can't afford your analog prescription, tell your clinician — they can help make the switch safer, or look at alternatives.

340B and community health centers

Federally Qualified Health Centers (FQHCs) and other 340B-covered entities receive sharply discounted prices on outpatient drugs, including insulin. Many pass at least some of those savings on to patients on a sliding-scale basis. Community health centers operate in every state and territory; the federal HRSA "Find a Health Center" tool lists them. Many serve patients regardless of insurance status.

Other options

• State pharmaceutical assistance programs. Many states have programs for older adults, people with disabilities, or people with low income.
• GoodRx and similar discount cards. They do not work with insurance, but they sometimes beat insurance cash prices for cash-paying patients.
• 340B mail-order pharmacies through some health systems.
• Hospital charity care. Nonprofit hospitals are required to have financial assistance policies for the hospital care they provide. Some also help with medications, so it is worth asking; these programs are often poorly advertised but real.
• Civica, a nonprofit drug company, has sold insulin glargine-yfgn (interchangeable with Lantus) since January 2026, at a suggested maximum retail price of $55 for a box of five pens (no more than $30 for a vial, where sold); it needs a prescription but no enrollment. In California the same product is sold as CalRx insulin glargine. Civica's rapid-acting aspart is still in development; check its website for current availability.
• Online cash-price pharmacies sell some diabetes medicines at published prices; insulin availability varies, so compare with your insurance price before switching.

If you cannot afford insulin this week — do this

In order, until something works:

1. Call your prescriber's office. Tell them you cannot afford this prescription. Some offices have samples or other short-term options while a longer-term plan is built. They can also switch the prescription to a lower-cost biosimilar or to ReliOn safely.
2. Contact the manufacturer program for your insulin (websites above). Ask about the savings card and the patient assistance program.
3. Ask the pharmacist what the cash price is for the same insulin under any savings card or coupon, and whether a biosimilar is available.
4. Walk into a Walmart for ReliOn if a same-day option is needed and your prescriber agrees. Regular and NPH are sold without a prescription in most states.
5. Find a Federally Qualified Health Center using HRSA's Find a Health Center tool. Many can see new patients on short notice and can prescribe at 340B prices.
6. Contact a diabetes nonprofit. Organizations such as Breakthrough T1D (formerly JDRF), Beyond Type 1, and the American Diabetes Association maintain resource lists for people who cannot afford insulin.
7. Go to an emergency department if you have run out, or if you feel unwell with high blood sugar, and cannot reach any of the above. U.S. emergency departments must evaluate and stabilize anyone who arrives (under the federal EMTALA law), regardless of ability to pay.

What you should not do is silently stretch your insulin — using less than prescribed to make supplies last. U.S. surveys have found that a substantial minority of people who use insulin — around one in four in one widely cited 2019 study — have used less than prescribed because of cost. Missing insulin is a common trigger of DKA, which costs more, hurts more, and can kill. The phone calls above are uncomfortable; the alternative is much worse.

Sources

• CMS: Frequently asked questions about Medicare insulin cost-sharing changes (Part D)
• CMS: Billing Medicare Part B for insulin with new limits (pump insulin)
• Eli Lilly: Lilly Insulin Value Program
• Novo Nordisk: MyInsulinRx program terms
• Novo Nordisk Pharma, Inc.: discontinuation of unbranded Insulin Aspart and Insulin Degludec
• Sanofi: expansion of the Insulins Valyou Savings Program (September 2025)
• CalRx (State of California): Biosimilar Insulin Initiative
• Civica Rx
• HRSA: Find a Health Center

Frequently asked questions